Intense Regulated Pulse Light Therapy in Dry Eye Disease

Status Recruiting

Clinical Trial Summary

The aim of this study is to assess the effect of intense regulated pulse light (IRPL) on the treatment of Dry eye.

Clinical Trial Description

Dry eye disease is a common ocular condition that needs prompt diagnosis and careful treatment interventions. If left untreated, it can lead to numerous sight threatening complications, including ulceration of the cornea, blepharitis, alterations of the tear film, conjunctivitis, and in severe cases, significant drying of the eye may lead to scarring, thinning, and even perforation of the cornea. Intense pulsed light (IPL) therapy is a new treatment strategy for treatment of MGD by inducing the restoration of the normal activity of the meibomian glands. In fact, IPL has been used for treating the patients with facial telangiectasias and erythema of rosacea and also resulted in improvement in ocular surface health. Evaporative form is the commonest form of DED and it is mainly caused by meibomian glands dysfunction (MGD). The usual traditional treatment options for MGD include warm compresses, expression of meibomian glands (MG), anti-inflammatory drugs, and lubricant eye drops. The aim of this study is to assess the effect of intense regulated pulse light (IRPL) on the treatment of Dry eye. The study included 34 patients with moderate to severe evaporative dry eye. The symptoms will be assessed with the Dry Eye-Related Quality of Life Score (DEQ-5) Questionnaire. The tear film will be assessed through MediWorks D130+S390L (WDR) which is a device attached to the slit lamp for non-invasive examination of tear film. Patients will be divided into 2 groups: The 1st group include (17) patients who will be treated with Intense Regulated Pulse Light (IRPL) & the 2nd group include (17) patients will treated by traditional methods of MGD as Eyelid hygiene, topical lubricant, topical & systemic antibiotics & anti-inflammatory agents IRPL will be done using E-Eye (E-Swin, France) & each patient will undergo 3 sessions on Day (1), Day (15), and Day (45). The patients will be reassessed after the 3rd session. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05553561
Study type	Interventional
Source	Menoufia University
Contact	Rofaida Mostafa Mansour, Master degree in ophthalmology
Phone	01000502442
Email	drrofaidamostafa1989@gmail.com
Status	Recruiting
Phase	N/A
Start date	January 1, 2023
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03216096` - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease	Phase 1
Completed	`NCT05825599` - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms	N/A
Completed	`NCT04656197` - The Ocular Microbiome in Patients With Dry Eye Disease
Completed	`NCT05031806` - Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease	Phase 1
Completed	`NCT03688802` - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation	Phase 2
Completed	`NCT05213156` - Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease	Phase 4
Completed	`NCT04548427` - Study to Evaluate the Efficacy and Safety of CKD-352	Phase 3
Completed	`NCT06176651` - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers	Phase 4
Completed	`NCT02254265` - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca	Phase 2/Phase 3
Completed	`NCT00395759` - The Visual Effect of an Investigational Artificial Tear in the Tear Layer.	N/A
Completed	`NCT00680108` - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution	Phase 2
Recruiting	`NCT06064071` - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD	N/A
Completed	`NCT04139122` - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease	Phase 1/Phase 2
Not yet recruiting	`NCT06375343` - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®	Phase 1
Completed	`NCT01468168` - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients	Phase 2
Completed	`NCT01014078` - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease	Phase 4
Completed	`NCT00799682` - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®	Phase 4
Completed	`NCT05082974` - Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)	Phase 3
Recruiting	`NCT06146881` - Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia	Phase 2
Completed	`NCT03292809` - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)	Phase 2/Phase 3